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Tackling cancers of unmet need: the pancreatic cancer pathway
Pancreatic cancer outcomes are unyieldingly poor even 
despite improvement in the overall picture for many 
cancers. Pancreatic cancer is the tenth most common 
cancer in the UK, and demographic changes, such as 
ageing and the increasing prevalence of diabetes, have 
precipitated a rise in incidence. Survival, however, has 
remained steady since the 1970s, with 10-year survival 
of 1%. Such fi gures justify the positioning of pancreatic 
cancer as a cancer of signifi cant unmet need.
Reasons for the persistently poor outlook are complex, 
but the diagnostic pathway is clearly important. Prompt 
diagnosis of pancreatic cancer is challenging: common 
early symptoms typically signify benign disease, and 
are often attributed to the ageing process or coexisting 
disorders. Symptom appraisal issues are common across 
several cancer types, and delays can occur both within 
the patient interval (the time from fi rst symptom onset 
to fi rst consultation) and the primary care interval 
(the time from consultation to specialist referral). 
The total diagnostic interval is longer for pancreatic 
cancers than for other cancers, including  others of 
unmet need.1 Moreover, almost half of all pancreatic 
cancers are diagnosed via emergency presentation.2
Disentangling delay is notoriously complex. Models 
that categorise the total diagnostic interval show the 
many infl uences, including patient, practitioner, and 
social and environmental factors, that can aff ect the 
diagnostic pathway,3 but much of what we know has 
been learnt retrospectively. Retrospective accounts are 
far from ideal because they can compromise accurate 
recall and, even unwittingly, the symptom appraisal 
period will be strongly infl uenced by the subsequent 
diagnosis.4
In The Lancet Gastroenterology & Hepatology, 
Fiona Walter and colleagues5 attempt to overcome 
this diffi  culty with the latest study from the suite of 
SYMPTOM studies,6,7 which include lung, colorectal, 
and, of interest here, pancreatic cancer. The studies 
provide an important prospective exploration of the 
time from symptom recognition to referral for specialist 
care, thus allowing a comparison of symptom profi les 
in patients with and without cancer. The pancreatic 
cancer study explores infl uences on the total diagnostic 
interval, including symptom and other patient factors, 
such as age, sex, and socioeconomic deprivation. 
With data from various sources (patients, and primary 
care and hospital records) the investigators report a 
thorough investigation of the prevalence of symptoms 
among people referred with symptoms associated with 
pancreatic cancer.
Of 391 people sampled, 119 (30%) participants 
were diagnosed with pancreatic cancer and 47 (12%) 
were diagnosed with other cancers. Of participants 
with pancreatic cancer, 56% had non-metastatic 
disease. Despite a poor response rate (24%), which 
is acknowledged as a key limitation of the study, the 
investigators present important fi ndings related to 
patterns of presenting symptoms relevant to primary 
care and specialist audiences alike, most notably the 
tendency towards the presence of multiple rather than 
single symptoms.
A total of 161 (41%) patients presented with a single 
fi rst symptom, whereas 212 (54%) patients had multiple 
fi rst symptoms. The most common initial symptoms 
were indigestion, loss of appetite, fatigue, and feeling 
diff erent, none of which were reported more frequently 
in the cancer group than in the no cancer group. 
Subsequent symptoms of jaundice, change in stool 
or urine colour, weight loss, fatigue, change in bowel 
habits, loss of appetite, and feeling diff erent were all 
more common in patients with pancreatic cancer than 
in those with no cancer. As with symptom patterns, 
no notable diff erences in total diagnostic interval 
were reported between patients with and those with 
no cancer (median 117 days [IQR 57–234] vs 131 days 
[66–284]; p=0·32). However, patients with metastatic 
pancreatic cancer had longer overall diagnostic 
intervals than did those with non-metastatic disease 
(136 days [86–323] vs 108 days [47–222]; p=0·13). 
The investigators also reported notable associations 
between type of symptom and diagnostic intervals, 
for example, jaundice and loss of appetite resulted in 
shorter total diagnostic intervals, whereas a range of 
common symptoms, such as back pain and self-reported 
anxiety or depression, or both, were associated 
with longer intervals. Diabetes was also associated with 
longer intervals.
Walter and colleagues’ fi ndings echo those of previous 
studies,8 but the absence of predictive initial symptoms 
coupled with the reporting of multiple symptoms 
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is noteworthy and poses particular challenges for 
both patients and health professionals. Evans and 
colleagues9 found that the intermittent nature of 
symptoms, including indigestion, wrongly reassured 
patients that their symptoms did not indicate serious 
disease and consequently prolonged help-seeking. 
In this study, longer health system intervals were 
associated with problems commonly seen in primary 
care, including coexisting morbidity, such as diabetes 
and anxiety and depression. Awareness campaigns 
tend to focus on alarm or red-fl ag symptoms, and 
emphasise pervasiveness. Evans and colleagues’ report 
suggests that such an approach requires a considerable 
rethink if pancreatic cancer is to be diagnosed more 
promptly. Such a rethink would be challenging 
because an emphasis on vague, intermittent, or mild 
symptoms is likely to have a considerable eff ect on an 
already stretched primary care system; importantly, 
it could lead to over investigation, which can also be 
harmful,10 because one test could lead to a cascade of 
further investigations that might themselves carry 
risks and result in adverse eff ects. The lowering of 
referral thresholds by the National Institute for Health 
and Care Excellence will, if adhered to, along with 
any further attempts to shorten the total diagnostic 
interval, have repercussions for health services as a 
whole, and additional resources will be needed to meet 
increased demand.11 Advancing screening options 
might off er a promising solution to overdiagnosis, but 
this requires not only the identifi cation of an eff ective 
test, but also agreement about its suitability within the 
target high-risk population. In the absence of adequate 
screening options at present, work that seeks to better 
understand and therefore improve the diagnostic 
pathway of pancreatic cancer should continue. 
*Sara Macdonald, Frances Mair
General Practice and Primary Care, Institute of Health and 
Wellbeing, University of Glasgow, Glasgow G12 9LX, UK
sara.macdonald@glasgow.ac.uk
FM has received grants from Oncimmune, outside the submitted work. 
SM declares no competing interests.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access 
article under the CC BY-NC-ND license.
1 Lyratzopoulos G, Abel GA, McPhail S, Neal RD, Rubin GP. Measures of 
promptness of cancer diagnosis in primary care: secondary analysis of 
national audit data on patients with 18 common and rarer cancers. 
Br J Cancer 2013; 108: 1550–51.
2 National Cancer Intelligence Network. Routes to diagnosis. http://www.
ncin.org.uk/publications/routes_to_diagnosis (accessed Aug 20, 2016).
3 Walter F, Webster A, Scott S, Emery J. The Andersen model of total patient 
delay: a systematic review of its application in cancer diagnosis. 
J Health Serv Res Policy 2012; 17: 110–18.
4 Andersen RS, Vedsted P, Olesen F, Bro F, Søndergaard J. Patient delay in 
cancer studies: a discussion of methods and measures. BMC Health Serv Res 
2009; 9: 189.
5 Walter FM, Mills K, Mendonça SC, et al. Symptoms and patient factors 
associated with diagnostic intervals for pancreatic cancer (SYMPTOM 
pancreatic study): a prospective cohort study. Lancet Gastroenterol Hepatol 
2016; published online Oct 4. http://dx.doi.org/10.1016/
S2468-1253(16)30079-6.
6 Walter FM, Emery JD, Mendonça S, et al. Symptoms and patient factors 
associated with longer time to diagnosis for colorectal cancer: results from 
a prospective cohort study. Br J Cancer 2016; 115: 533–41.
7 Walter FM, Rubin G, Bankhead C, et al. Symptoms and other factors 
associated with time to diagnosis and stage of lung cancer: a prospective 
cohort study. Br J Cancer 2015; 112 (suppl 1): S6–13.
8 Holly EA, Chaliha I, Bracci PM, Gautam M. Signs and symptoms of 
pancreatic cancer: a population-based case–control study in the 
San Francisco Bay area. Clin Gastroenterol Hepatol 2004; 2: 510–17.
9 Evans J, Chapple A, Salisbury H, et al. “It can’t be very important because it 
comes and goes”—patients’ accounts of intermittent symptoms preceding a 
pancreatic cancer diagnosis: a qualitative study. BMJ Open 2014; 4: e004215.
10 Redberg R, Katz M, Grady D. Diagnostic tests: another frontier for less is 
more: or why talking to your patient is a safe and eff ective method of 
reassurance. Arch Intern Med 2011; 171: 619–23.
11 National Institute for Health and Care Excellence. Suspected cancer: 
recognition and referral. June 23, 2015. https://www.nice.org.uk/guidance/
ng12/resources/suspected-cancer-recognition-and-
referral-1837268071621 (accessed Aug 20, 2016).
